Morepen Laboratories : Investors presentation - Q1' FY 2023-24

Date: 07/08/2023
To,
National Stock Exchange of India Ltd.	BSE Limited
Exchange Plaza, Bandra Kurla Complex,	Floor 25, Phiroze Jeejeebhoy Towers,
Bandra (East), Mumbai- 400 051	Dalal Street, Mumbai- 400 001
Symbol: MOREPENLAB	Scrip Code: 500288

Subject: Investors Presentation (Q1'FY24) August, 2023

Dear Sir/Ma'am,

Please find enclosed the Investors Presentation (Q1'FY24) August, 2023, based on the financial performance of the company for the quarter ended 30th June 2023.

Kindly take it on your record.

Thanking you.

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava

Company Secretary

Encl.: As Above

Morepen Laboratories Limited

CIN No: L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector 20, Gurugram, Haryana-122016, INDIA

Tel.: [phone], E-mail: [e-mail], Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA

Tel.: [phone], 244590, Fax: [phone],E-mail: [e-mail]

MOREPEN

LABORATORIES LIMITED

Q1'FY24

earnings Presentation - aug 2023

Disclaimer/ Confidentiality

This presentation has been prepared by Morepen Laboratories Limited ("Company") solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking statements, including discussions of our future plans, strategy, research and deployment activities and products in pipeline. Such forward looking statements reflect current views of the Company or its subsidiaries regarding future events, and involve known or unknown risks, uncertainties and other factors that may cause actual results to be different from any future results expressed or implied by such statements.

This presentation has been prepared by the Company based on information an data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. The Company is providing the information in this presentation as of date and does not undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise.

The contents of this presentation are confidential and should not be distributed, published or reproduced, in whole or part, or disclosed by recipients, either directly or indirectly, to any other person. It is advised that prior to acting upon this presentation independent consultation / advice may be obtained and necessary due diligence, investigations, etc. may be conducted at the end of the recipient.

This presentation does not constitute or form part of and should not be construed, either directly or indirectly, as any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company by any person in any jurisdiction. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India.

This presentation contain confidential data and information about the company historical performance and future business plan strategy and the any reader/user can not copy, circuculate or use disclose the said information or part of it to anyone without prior written permission of the Company. Any unauthorised use of the data will attract legal action against the person.

.

Q 1 ' F Y 2 4 p e r f o r m a n c e

Rs. in crores

^33%

N e t R e v e n u e

303.31 403.46

Q1'FY23 Q1'FY24

C O N S O L I D A T E D

QUARTERLY HIGHLIGHTS

Rs. in crores

^147%

388404

Profit before Tax

303

259

8.31 20.51

Q1'FY23 Q1'FY24

multifold jump in the export to US market from

baddi facility

C O N S O L I D A T E D

QUARTERLY HIGHLIGHTS

Business is on growth path once again, last year there was contraction of 22% in Q1FY' 23 revenues.

Quarterly revenues of Rs. 403 Cr. from Rs. 303 Cr Q1'FY23 revenues, up 33% on y-o-y basis on account of:

135% jump in Exports to US market with new orders post US FDA approval of Fexofinadine (Allegra)

48% jump in Medical Devices business with buoyant demand Long term revenue growth is outstanding with CAGR of 19% over last 4 years despite ups and downs of Covid period.

There is a visible increase in the overall EBITDA by 196bps and PBT moved up 234 bps and PAT goes up by 177bps

Profit before Tax at Rs. 20.51 crores has substantially improved over corresponding quarter last year with growth of 147%.

Company has increased its marketing and distribution budgets for deeper market penetration and brand recall and getting better share of the market in medical devices business